@ARTICLE{10.3389/fphar.2018.00801, AUTHOR={Chu, Ming and Chen, Xi and Wang, Jing and Guo, Likai and Wang, Qianqian and Gao, Zirui and Kang, Jiarui and Zhang, Mingbo and Feng, Jinqiu and Guo, Qi and Li, Binghua and Zhang, Chengrui and Guo, Xueyuan and Chu, Zhengyun and Wang, Yuedan}, TITLE={Polypharmacology of Berberine Based on Multi-Target Binding Motifs}, JOURNAL={Frontiers in Pharmacology}, VOLUME={9}, YEAR={2018}, URL={https://www.frontiersin.org/articles/10.3389/fphar.2018.00801}, DOI={10.3389/fphar.2018.00801}, ISSN={1663-9812}, ABSTRACT={Background: Polypharmacology is emerging as the next paradigm in drug discovery. However, considerable challenges still exist for polypharmacology modeling. In this study, we developed a rational design to identify highly potential targets (HPTs) for polypharmacological drugs, such as berberine.Methods and Results: All the proven co-crystal structures locate berberine in the active cavities of a redundancy of aromatic, aliphatic, and acidic residues. The side chains from residues provide hydrophobic and electronic interactions to aid in neutralization for the positive charge of berberine. Accordingly, we generated multi-target binding motifs (MBM) for berberine, and established a new mathematical model to identify HPTs based on MBM. Remarkably, the berberine MBM was embodied in 13 HPTs, including beta-secretase 1 (BACE1) and amyloid-β1-42 (Aβ1-42). Further study indicated that berberine acted as a high-affinity BACE1 inhibitor and prevented Aβ1-42 aggregation to delay the pathological process of Alzheimer’s disease.Conclusion: Here, we proposed a MBM-based drug-target space model to analyze the underlying mechanism of multi-target drugs against polypharmacological profiles, and demonstrated the role of berberine in Alzheimer’s disease. This approach can be useful in derivation of rules, which will illuminate our understanding of drug action in diseases.} }